What is the FDA approved drug for bronchiectasis?
•
4 min read
For decades, patients with bronchiectasis relied solely on supportive care and antibiotics, with no therapy specifically approved to target the underlying disease. The U.S. Food and Drug Administration (FDA) made a historic decision on August 12, 2025, by approving Brinsupri (brensocatib), the first medication specifically indicated to treat non-cystic fibrosis (non-CF) bronchiectasis.
